Journal
SURGICAL INFECTIONS
Volume 19, Issue 8, Pages 757-768Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/sur.2018.233
Keywords
active immunity; adaptive immunity; passive immunity; Pseudomonas aeruginosa; T(H)17; vaccine
Categories
Funding
- Cystic Fibrosis Foundation [PRIEBE17G0]
- Richard A. and Susan F. Smith President's Innovation Award
- Technology and Innovation Development Office (TIDO) at Boston Children's Hospital
- Translational Research for Infection Prevention in Pediatric Anesthesia and CriticalCare (TRIPPACC) Program of the Department of Anesthesiology, Critical Care and Pain Medicine at Boston Children's Hospital
Ask authors/readers for more resources
Background: The gram-negative bacterial pathogen Pseudomonas aeruginosa causes a wide range of infections, mostly in hospitalized and immunocompromised patients, those with burns, surgical wounds, or combat-related wounds, and in people with cystic fibrosis. The increasing antibiotic resistance of P. aeruginosa confers a pressing need for vaccines, yet there are no P. aeruginosa vaccines approved for human use, and recent promising candidates have failed in large clinical trials. Discussion: In this review, we summarize recent clinical trials and pre-clinical studies of P. aeruginosa vaccines and provide a suggested framework for the makeup of a future successful vaccine. Murine models of infection suggest that antibodies, specifically opsonophagocytic killing antibodies (OPK), antitoxin antibodies, and anti-attachment antibodies, combined with T cell immunity, specifically T(H)17 responses, are needed for broad and potent protection against P. aeruginosa infection. A better understanding of the human immune response to P. aeruginosa infections, and to vaccine candidates, will eventually pave the way to a successful vaccine for this wily pathogen.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available